The PPP1R8 gene plays a significant role in cardiac function and development. Mutations in this gene have been linked to various cardiac defects, emphasizing the importance of genetic testing for individuals at risk. The PPP1R8-related genetic test is a specialized diagnostic tool designed to identify mutations within the PPP1R8 gene that could lead to cardiac abnormalities. This test is particularly crucial for families with a history of heart defects or individuals showing symptoms related to cardiac dysfunction, as early detection can significantly influence management and treatment options.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the PPP1R8 genetic test employs advanced molecular techniques to ensure accurate and reliable results. The test is priced at 4400 AED, reflecting the sophisticated technology and expertise involved in its execution. Upon completion, the test provides invaluable insights into the patient's genetic profile concerning the PPP1R8 gene, aiding healthcare professionals in developing personalized treatment plans and offering genetic counseling based on the identified risks.
This genetic test represents a critical step towards proactive cardiac health management, enabling at-risk individuals to take informed steps towards prevention, early intervention, and optimized care for potential heart-related conditions.
The "FLNA Gene Cardiac Valvular Dysplasia X-Linked Genetic Test" is a specialized diagnostic tool designed to identify mutations in the FLNA gene, which are associated with X-linked cardiac valvular dysplasia. This condition is a rare form of heart disease that affects the heart valves, leading to abnormalities in their structure and function. Since the FLNA gene plays a crucial role in cellular structure and signaling, mutations in this gene can disrupt the normal development and function of heart valves, potentially resulting in a range of cardiac issues.
This genetic test is vital for early detection and management of the condition, particularly in families with a history of X-linked cardiac valvular dysplasia. Early diagnosis through genetic testing can aid in the timely initiation of treatment strategies, potentially improving the quality of life and prognosis for affected individuals.
The test is available at DNA Labs UAE, a leading facility in genetic testing and analysis, ensuring high standards of accuracy and reliability. The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the analysis and the specialized expertise required to interpret the results. Opting for this test at DNA Labs UAE ensures that patients and their families receive critical insights into their genetic health, enabling informed medical and lifestyle decisions in the context of X-linked cardiac valvular dysplasia.
The "SCO2 Gene Cardioencephalomyopathy Fatal Infantile Due to Cytochrome C Oxidase Deficiency Genetic Test" is a specialized diagnostic procedure aimed at detecting mutations in the SCO2 gene, which are known to cause a rare and severe form of cardioencephalomyopathy. This condition is characterized by fatal infantile onset, primarily due to a deficiency in cytochrome c oxidase (COX), an essential enzyme in the mitochondrial respiratory chain responsible for energy production in cells. Affected individuals may present with a range of symptoms including heart failure, neurological impairment, and muscle weakness, among others.
The test involves analyzing the patient's DNA to identify mutations in the SCO2 gene that lead to the enzyme deficiency, thus confirming the diagnosis of this specific form of cardioencephalomyopathy. Early and accurate detection through genetic testing is crucial for managing the condition, as it can guide treatment decisions and help in assessing the risk for future pregnancies within the family.
This genetic test is available at DNA Labs UAE, a facility known for its advanced diagnostic services and genetic testing capabilities. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the genetic mutations associated with this condition. For families facing the devastating impact of this disease, the test offers a vital tool in understanding and managing the condition more effectively.
The COX15 gene cardioencephalomyopathy fatal infantile due to cytochrome c oxidase deficiency type 2 is a rare genetic disorder characterized by severe multi-organ dysfunction that primarily affects the heart and brain. This condition is caused by mutations in the COX15 gene, which plays a critical role in the assembly of cytochrome c oxidase, an essential component of the mitochondrial respiratory chain responsible for energy production in cells.
Patients with this disorder typically present with symptoms early in life, including hypertrophic cardiomyopathy, lactic acidosis, and neurodevelopmental delay, leading to early infantile death. Diagnosis of this condition relies on genetic testing to identify mutations in the COX15 gene.
In the United Arab Emirates, DNA Labs UAE offers a specialized genetic test for diagnosing this condition. The test costs 4400 AED and involves analyzing the patient's DNA to detect mutations in the COX15 gene. This genetic test is crucial for confirming the diagnosis, allowing for appropriate management and counseling of affected families. DNA Labs UAE is equipped with advanced technology and expertise to provide accurate and reliable results for this complex genetic test.
The COA5 Gene Cardioencephalomyopathy Fatal Infantile Due to Cytochrome C Oxidase Deficiency Type 3 Genetic Test is a specialized diagnostic assessment carried out to detect mutations in the COA5 gene, which are linked to a rare but severe condition. This condition, characterized by heart and brain dysfunction, typically manifests in infancy and is caused by a deficiency in the enzyme cytochrome c oxidase. This enzyme is crucial for the cellular energy production process. Early detection through this genetic test is vital for managing symptoms and potentially improving quality of life, despite the condition's severity. The test, offered at DNA Labs UAE, is priced at 4400 AED. It represents a critical step towards personalized medicine for affected families, providing them with specific genetic insights related to this rare disorder.
The TGFB3 Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 1 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the TGFB3 gene that are associated with Arrhythmogenic Right Ventricular Cardiomyopathy Type 1 (ARVC1). ARVC1 is a form of heart disease characterized by the replacement of heart muscle with fatty and fibrous tissue, primarily affecting the right ventricle. This condition can lead to heart rhythm problems, heart failure, and an increased risk of sudden cardiac death, especially in young athletes.
The genetic test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any mutations in the TGFB3 gene that are linked to ARVC1. This test is crucial for individuals with a family history of ARVC1 or those who exhibit symptoms related to the condition, as early detection can lead to timely and potentially life-saving interventions.
The cost of the TGFB3 Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 1 Genetic Test at DNA Labs UAE is 4400 AED. Given the complexity of the test and the specialized analysis involved, the price reflects the comprehensive nature of this genetic screening. Identifying at-risk individuals through this test allows for the implementation of preventive measures, lifestyle adjustments, and monitoring strategies to manage the condition effectively and reduce the risk of complications.
The "DSG2 Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 10 Genetic Test" is a specialized diagnostic tool used to identify mutations in the DSG2 gene, which are associated with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Type 10. ARVC is a genetic condition characterized by progressive heart muscle disease, leading to fibrofatty replacement of the right ventricle, arrhythmias, and an increased risk of sudden cardiac death. The test specifically targets the DSG2 gene, one of the several genes linked to this condition, to confirm a diagnosis, assess the risk of developing the disease, or guide treatment decisions.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test is available for a cost of 4400 AED. DNA Labs UAE employs state-of-the-art technology and adheres to stringent quality controls to ensure accurate and reliable results. By opting for this test, individuals suspected of having ARVC Type 10 or those with a family history of the condition can gain valuable insights into their genetic makeup, facilitating early intervention and personalized management strategies to mitigate the risk of complications associated with the disease.
The DSC2 Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 11 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to detect mutations in the DSC2 gene, which are associated with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Type 11. ARVC is a form of heart disease that affects the muscle of the right ventricle, leading to arrhythmias and heart failure. The condition is genetic and can be passed down through families.
The test is particularly crucial for individuals with a family history of ARVC or unexplained cardiac symptoms, as early detection can significantly influence management and treatment options. By analyzing the patient's DNA, the test identifies specific mutations in the DSC2 gene that are known to contribute to the development of this condition, providing valuable information for clinical decisions.
Priced at 4400 AED, the test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities and commitment to providing accurate, confidential, and comprehensive diagnostic services. The cost reflects the intricate technology and expertise required to perform such specialized genetic analysis. This test is an essential tool in the arsenal against ARVC, offering hope and direction for affected individuals and their families in managing this challenging condition.
The JUP Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 12 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the JUP gene, which are linked to Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Type 12. ARVC is a genetic disorder that affects the muscle of the right ventricle of the heart, potentially leading to heart rhythm problems and heart failure. The test, costing 4400 AED, is crucial for individuals with a family history of ARVC or those displaying symptoms related to the condition. Early detection through this genetic testing can aid in the management and treatment planning for affected individuals, potentially improving their quality of life and reducing the risk of severe complications.
The TMEM43 Gene Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the TMEM43 gene. These mutations are associated with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Type 5, a rare form of cardiomyopathy that primarily affects the muscle of the right ventricle of the heart. This condition can lead to heart rhythm abnormalities, heart failure, and an increased risk of sudden cardiac death. The test is crucial for individuals with a family history of ARVC or those exhibiting symptoms related to the condition, as early detection can significantly impact management and treatment options. The cost of the test is set at 4400 AED, reflecting the specialized nature of the genetic analysis and the comprehensive insight it provides into the individual's risk of developing this serious heart condition.
